UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

September 5, 2022

Primary Completion Date

August 5, 2023

Study Completion Date

September 5, 2023

Conditions
COVID-19 PandemicCOVID-19 Vaccines
Interventions
BIOLOGICAL

Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg

"Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARSCoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial~(1 ml per vial). The vial should be shaken well before injection."

BIOLOGICAL

CoronaVac Biofarma COVID-1 9 Vaccine 3 µg

Control vaccine in this study is existing CoronaVacBioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia.

Trial Locations (1)

67161

RECRUITING

Dr. Soetomo General Hospital, Surabaya

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Indonesia-MoH

OTHER_GOV

collaborator

Universitas Airlangga

OTHER

collaborator

Bioxis Pharmaceuticalls

INDUSTRY

lead

Dr. Soetomo General Hospital

OTHER_GOV